Skip to main content

GoodRx Holdings, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

GDRX$3.54-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits and Financial Statement Schedules

(a)(1) Financial Statements

Our consolidated financial statements are included in this Annual Report on Form 10-K beginning on page F-1.

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted because they are not applicable, not material or because the

information required is already included in the consolidated financial statements or the notes thereto.

(a)(3) Exhibits

The exhibits listed below are filed as part of this Annual Report on Form 10-K or are incorporated herein by reference, in

each case as indicated below.

ExhibitNumber · Exhibit Description · Incorporated by Reference · Filed/FurnishedHerewith
Form · File No. · Exhibit · FilingDate
3.1Amended and Restated Certificate of Incorporation8-K001-395493.19/28/20
3.2Amended and Restated Bylaws8-K001-395493.29/28/20
4.1Form of Certificate of Class A Common StockS-1333-2484654.18/28/20
4.2Form of Certificate of Class B Common StockS-8333-2490694.49/25/20
4.3Description of Capital Stock10-K001-395494.32/29/24
4.4Amended and Restated Stockholders Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated October 12, 2018S-1333-2484654.28/28/20
4.5Stockholders Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated September 22, 20208-K001-3954910.19/28/20
4.6Amended and Restated Investor Rights Agreement by and between GoodRx Holdings, Inc. and certain security holders of GoodRx Holdings, Inc., dated October 12, 2018S-1333-2484654.48/28/20
10.1†Form of Indemnification Agreement between GoodRx Holdings, Inc. and its directors and officersS-1/A333-24846510.19/14/20
10.2†Fifth Amended and Restated 2015 Equity Incentive Plan10-Q001-3954910.211/12/20
10.3†2020 Incentive Award PlanS-1/A333-24846510.39/14/20
10.3.1†Form of Option Agreement pursuant to 2020 Incentive Award Plan (2020 Form)S-1/A333-24846510.3.19/14/20
10.3.2†Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan (2020 Form)S-1/A333-24846510.3.29/14/20
10.3.3†Form of Option Agreement pursuant to 2020 Incentive Award Plan (2025 Form)10-Q001-3954910.111/4/25
10.3.4†Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan (2025 Form)10-Q001-3954910.211/4/25
10.3.5†First Amendment to 2020 Incentive Award Plan10-Q001-3954910.15/13/21
10.4†GoodRx Holdings, Inc. 2020 Employee Stock Purchase PlanS-1/A333-24846510.49/14/20
10.5.1†Second Amended and Restated Employment Agreement, by and between GoodRx, Inc. and Trevor Bezdek, dated April 25, 20238-K001-3954910.24/25/23
10.5.2†First Amendment to Second Amended and Restated Employment Agreement, by and between GoodRx, Inc. and Trevor Bezdek, dated October 25, 20248-K001-3954910.110/28/24
10.6.1+First Lien Credit Agreement by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC, the lenders party thereto, Barclays Bank PLC and the joint lead arrangers and joint lead bookrunners party thereto, dated October 12, 2018S-1/A333-24846510.138/28/20
10.6.2+First Lien Security Agreement by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC., Iodine, Inc., and Barclays Bank PLC, dated October 12, 2018S-1/A333-24846510.168/28/20
10.6.3+First Lien Guaranty by and among GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc. and Barclays Bank PLC, dated October 12, 2018S-1/A333-24846510.178/28/20
10.6.4+First Incremental Amendment to First Lien Credit Agreement by and between GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc., HeyDoctor, LLC, the lenders party thereto and Barclays Bank PLC, dated November 1, 2019S-1/A333-24846510.148/28/20
10.6.5+Second Incremental Amendment to First Lien Credit Agreement by and between GoodRx, Inc., GoodRx Intermediate Holdings, LLC, Iodine, Inc., HeyDoctor, LLC, Lighthouse Acquisition Corp., the lenders party thereto and Barclays Bank PLC, dated May 12, 2020S-1/A333-24846510.158/28/20
10.6.6+Third Amendment to First Lien Credit Agreement, dated June 29, 202310-Q001-3954910.58/9/23
10.6.7+Fourth Amendment to First Lien Credit Agreement, dated July 7, 202310-Q001-3954910.68/9/23
10.6.8+Fifth Amendment to First Lien Credit Agreement, dated February 20, 20248-K001-3954910.12/26/24
10.6.9+Sixth Amendment to First lien Credit Agreement, dated July 10, 20248-K001-3954910.17/11/24
10.7.1^+Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated September 6, 2019S-1/A333-24846510.198/28/20
10.7.2^First Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated August 14, 202010-Q001-3954910.18/12/21
10.7.3^+Second Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated May 27, 202110-Q001-3954910.28/12/21
10.7.4Third Amendment to Office Lease Agreement by and between GoodRx, Inc. and CSHV Pen Factory, LLC, dated March 18, 202210-Q001-3954910.15/10/22
10.7.5Fourth Amendment to Office Lease Agreement by and between GoodRx, Inc. and Pen Factory Property Owner, LLC, dated February 7, 202410-Q001-3954910.15/9/24
10.7.6Fifth Amendment to Office Lease Agreement by and between GoodRx, Inc. and Pen Factory Property Owner, LLC, dated January 2, 202510-Q001-3954910.35/7/25
10.8†Offer Letter for Romin Nabiey, effective May 1, 201710-K001-3954910.193/1/23
10.9.1†Employment Agreement, by and between GoodRx, Inc. and Karsten Voermann, dated March 4, 20248-K001-3954910.13/7/24
10.9.2†Separation Agreement & General Release, by and between GoodRx, Inc. and Karsten Voermann, dated January 17, 202510-K001-3954910.12/27/25
10.10†Employment Agreement, by and between GoodRx, Inc. and Wendy Barnes, dated December 12, 20248-K001-3954910.112/16/24
10.10.1†Early Exercise Option Agreement, by and between GoodRx, Inc. and Wendy Barnes, dated March 3, 2025*
10.10.2†Retention Bonus Letter Agreement, by and between GoodRx, Inc. and Wendy Barnes, dated December 9, 20258-K001-3954910.112/12/25
10.11†Non-Employee Director Deferred Compensation Plan10-K001-3954910.182/29/24
10.11.1†Form of Director Deferred Cash Fees RSU Agreement10-K001-3954910.18.12/29/24
10.11.2†Form of Director Deferred RSU Agreement10-K001-3954910.18.22/29/24
10.11.3†Executive Severance Plan10-Q001-3954910.18/8/24
10.11.4†Second Amended and Restated Non-Employee Director Compensation Program, dated October 31, 2025*
10.12.1†Employment Agreement, by and between GoodRx, Inc. and Christopher McGinnis, dated February 4, 20258-K001-3954910.12/5/25
10.12.2†Retention Bonus Letter Agreement, by and between GoodRx, Inc. and Christopher McGinnis, dated December 9, 20258-K001-3954910.212/12/25
19.1Insider Trading Compliance Policy10-K001-3954919.12/27/25
21.1List of Subsidiaries of GoodRx Holdings, Inc.*
23.1Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm*
31.1Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer*
31.2Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer*
32.1Section 1350 Certification of Chief Executive Officer**
32.2Section 1350 Certification of Chief Financial Officer**
97.1†GoodRx Holdings Inc. Policy for Recovery of Erroneously Awarded Compensation10-K001-3954997.12/29/24
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
  • Filed herewith.

** Furnished herewith.

† Indicates management contract or compensatory plan.

^ Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is

treated as confidential by the Company.

  • The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5)(b)(2) of

Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule, or exhibit to

the SEC upon request.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.